Trials / Completed
CompletedNCT04456686
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 117 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to test the safety and efficacy of LY3016859 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3016859 | LY3016859 given IV. |
| DRUG | Placebo | Placebo given IV. |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2021-04-22
- Completion
- 2021-08-26
- First posted
- 2020-07-02
- Last updated
- 2023-11-14
- Results posted
- 2022-06-23
Locations
33 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04456686. Inclusion in this directory is not an endorsement.